Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results

Summary Patients with chronic lymphocytic leukaemia (CLL) whose tumour cells harbour a 17p deletion (17p‐) are universally considered to have a poor prognosis. The deletion can be detected at diagnosis or during the evolution of the disease, particularly in patients who have received chemotherapy. W...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2012-04, Vol.157 (1), p.67-74
Main Authors: Delgado, Julio, Espinet, Blanca, Oliveira, Ana C., Abrisqueta, Pau, de la Serna, Javier, Collado, Rosa, Loscertales, Javier, Lopez, Montserrat, Hernandez-Rivas, Jose A., Ferra, Christelle, Ramirez, Angel, Roncero, Josep M., Lopez, Cristina, Aventin, Anna, Puiggros, Anna, Abella, Eugenia, Carbonell, Felix, Costa, Dolors, Carrio, Anna, Gonzalez, Marcos
Format: Article
Language:English
Subjects:
17p
Adult
Age
Aged
Aged, 80 and over
beta 2-microglobulin
beta 2-Microglobulin - blood
Biological and medical sciences
Cell survival
Chemotherapy
Chromosome Deletion
Chromosomes, Human, Pair 17
Chronic lymphatic leukemia
chronic lymphocytic leukaemia
Clonal deletion
Data processing
Disease-Free Survival
Evolution
Female
Fluorescence in situ hybridization
Follow-Up Studies
Hematologic and hematopoietic diseases
Humans
In Situ Hybridization, Fluorescence
Leukemia, Lymphocytic, Chronic, B-Cell - blood
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Leukemia, Lymphocytic, Chronic, B-Cell - therapy
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Prognosis
Retrospective Studies
Smith-Magenis Syndrome
Survival Rate
TP53
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Patients with chronic lymphocytic leukaemia (CLL) whose tumour cells harbour a 17p deletion (17p‐) are universally considered to have a poor prognosis. The deletion can be detected at diagnosis or during the evolution of the disease, particularly in patients who have received chemotherapy. We sought to evaluate the natural history of patients with 17p‐ CLL, identify predictive factors within this prognostic subgroup, and evaluate the results of different therapeutic approaches. Data from 294 patients with 17p‐ CLL followed up at 20 different institutions was retrospectively collected and analysed. Median age was 68 (range 27–98) years at the time of fluorescence in situ hybridization analysis. After 17p‐ documentation, 52% received treatment, achieving an overall response rate of 50%. Median overall survival was 41 months, and was significantly shorter in patients with elevated beta2‐microglobulin concentration (P 
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2011.09000.x